NADAL® COVID-19 IgG/IgM Rapid Test – Antibody Test.
Rapid test for the detection of anti-SARS-CoV-2 IgG and IgM in human whole blood, serum or plasma samples.
The NADAL® COVID-19 IgG/IgM Test is a chromatographic immunoassay in lateral flow format for the qualitative detection of anti-SARS-CoV-2 IgG and IgM in human whole blood, serum or plasma samples. Note that in the early stages of infection, anti-SARS-CoV-2 IgG and IgM may be below the detection limit of the test. The test should be viewed as an aid in the diagnosis of primary infections and possible secondary infections with SARS-CoV-2.
Features of the test:
- Test from Germany.
- High sensitivity and specificity.
- Easy handling.
- Fast and reliable test results in only 10 – 20 minutes.
- Can be performed with whole blood (from vein or finger puncture), serum or plasma.
- Test storage at room temperature.
- Use only by medically trained personnel.
About the virus
The name “coronavirus” is due to the characteristic, wreath-shaped appearance of the surface proteins (so-called spikes) of its envelope (Latin “corona”: wreath, crown). The family Coronaviridae (CoV) includes 2 subfamilies, 5 genera, 23 subgenera, and circa 40 species known to date. Many of these viruses cause disease in mammals and birds and can be transmitted from animals to humans. Human coronaviruses (hCoVs) were first described in 1965. The human pathogenic representatives known so far are mainly assigned to the genus Betacoronaviruses. They can cause diseases such as colds and bronchitis
but also cause severe acute respiratory infections (SARI) or pneumonia.
Tentatively referred to as 2019-nCoV and officially as SARS-CoV-2, the currently discussed coronavirus is generally the 7th known and 3rd human pathogenic coronavirus in the last 2 decades. It follows Severe Acute Respiratory Syndrome (SARSCoV) in 2002 and Middle East Respiratory Syndrome (MERS-CoV) in 2012. The clinical manifestation of the current SARS-CoV-2 is officially designated COVID-19.